Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could skipping some neck radiation spare patients side effects?

NCT ID NCT07755449

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial is testing whether it is safe to skip radiation to certain low-risk areas of the neck after surgery for head and neck cancer. The goal is to see if this approach can reduce side effects and preserve quality of life while still keeping the cancer from coming back. Participants will receive standard radiation to the main tumor area, but not to the neck regions that were surgically cleared of cancer. The study will compare their outcomes to historical data from patients who received full neck radiation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiotherapy (IMRT or VMAT) that selectively omits radiation to low-risk neck areas, with optional concurrent cisplatin chemotherapy
What this could lead to
If successful, this approach could reduce side effects and improve quality of life for head and neck cancer patients after surgery, without increasing the risk of cancer returning.
What could go wrong
This is a phase II trial with a modest number of patients, and the strategy may not be as effective as standard radiation in preventing cancer recurrence. There is also a risk of increased recurrence in the omitted areas.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 101 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥ 18 years of age * ECOG Performance Status (PS) ≤ 2 * Histologically confirmed diagnosis of locally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx * Resection of the primary tumor and unilateral and/or bilateral neck dissection performed according to standard guidelines, with detailed histological reporting by nodal level * Number of lymph nodes per dissected neck ≥ 18 * No pathological lymph nodes following neck dissection (pN0) * Presence of a single pathological cervical lymph node following neck dissection (pN1), provided that: * No extracapsular extension * Diameter \< 1 cm * No skip metastasis * Presence of risk factors indicating postoperative radiotherapy. Stages pT1-pT2N1 and pT3-pT4N0/N1. If N1, all of the following criteria must be met: presence of a single cervical lymph node without extracapsular extension, diameter \< 1 cm, and no skip metastasis * Patients may receive adjuvant systemic treatment if surgical margins are positive or close (\< 5 mm) Exclusion Criteria: * Absence of informed consent * Prior irradiation to the head and neck region * Prior surgery in the head and neck region * Contralateral neck dissection not performed when clinically indicated * History of malignancy within the previous 5 years, with the exception of non-melanoma skin cancer * Interval between surgery and radiotherapy \> 8 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced head and neck squamous cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institut Català d'Oncologia

    RECRUITING

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.